Skip to main content
. 2017 Jan 3;8(8):12764–12774. doi: 10.18632/oncotarget.14463

Figure 4. HHT combination ibrutinib inhibits BCL-2 family signaling.

Figure 4

(A and C) MV4-11 and MOLM-13 cells were treated with 4 nM HHT and/or 1.25 ibrutinib for 6 h. (B and D) MV4-11, MOLM-13 and primary AML cells were treated with 8 nM HHT and/or 2.5 μM ibrutinib for 6 h. Western blot analysis was conducted for p-Bad, Bad, Bax, Bcl-2, Bcl-xL and Mcl-1protein levels.